NMS-01940153E

DRUG2 trials

Sponsors

Nerviano Medical Sciences S.r.l., Nerviano Medical Sciences

Conditions

Unresectable Hepatocellular Carcinoma (HCC)

Phase 1

Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

TerminatedNCT05630937

Nerviano Medical SciencesUnresectable Hepatocellular Carcinoma (HCC)

Start: 2020-11-13End: 2024-08-06Updated: 2025-06-19

Phase 2

Phase II Combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors

Active, not recruitingCTIS2024-516737-12-00

Nerviano Medical Sciences S.r.l.Unresectable Hepatocellular Carcinoma (HCC)

Start: 2025-01-28Target: 90Updated: 2025-08-19

Related Papers

Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.

Journal of Clinical Oncology2023-06-01